Levity Inc. dba Levity
Has Levity received an FDA warning letter? Yes. FDA issued a warning letter dated February 20, 2026 concerning products containing semaglutide and liraglutide.
Letter facts
- Letter date
- February 20, 2026 (2026-02-20)
- Issuing office
- Center for Drug Evaluation and Research (CDER)
- Recipient type
- Telehealth
- Products named
- compounded drug productssemaglutide drug productsliraglutide drug products
- Violation categories
- MisbrandingFalse or misleading claims
Understanding these violation categories
Misbranding
FDA says the products' labeling, promotion, or directions did not meet federal requirements, such as lacking adequate directions for use or making unsubstantiated claims. A warning letter is FDA's notice of what it believes are significant violations.
False or misleading claims
FDA says the company made claims regarding product equivalence, safety, or FDA approval that were inaccurate or not supported by evidence. A warning letter notifies the recipient to bring promotions into compliance.
Factual Violation Summary
FDA says the website falsely presents Levity as compounder of semaglutide and liraglutide and claims they contain the same ingredient as Ozempic/Wegovy or the power of Saxenda, implying FDA approval; products are misbranded.
Active Drug Ingredients
Statutory Citations & Specific Allegations
- misbranding
- false or misleading labeling
- false or misleading advertising or promotion
- misrepresentation of manufacturer or compounder
- implied FDA approval
More letters about Liraglutide
Recent FDA warning letters concerning Liraglutide:
- Momentum HealthJune 8, 2026
- Novo Nordisk Inc.March 5, 2026
- ZappyFebruary 20, 2026
- Novo Nordisk Inc.September 9, 2025
Similar violations (Misbranding)
Recent warning letters with related regulatory findings:
- RonanRxOctober 30, 2026
- Cheap Medicine ShopSeptember 24, 2026
- Online Generic MedicineSeptember 23, 2026
- Empower PharmacySeptember 18, 2026
- Tex PeptidesAugust 24, 2026
Regulatory Compliance & Editorial Standard:
The information on this page is compiled strictly from public regulatory enforcement documents published by the U.S. Food and Drug Administration (FDA) and reflects official government records at the time of issuance.
Regulatory Notice: Addressed establishments may have implemented corrective actions or entered into compliance agreements with regulatory authorities. For subsequent remedial filings or official FDA closeout letters, refer directly to the FDA.gov source link above.